COVID-19 vaccine developed by China’s CanSino to continue advancing phase-3 trials: report

BEIJING, Feb. 3 (Xinhua) — China’s CanSino Biologics Inc. has got green light to continue phase-3 trials of its COVID-19 vaccine with the support of findings of an independent data monitoring committee, said recent media reports.

The independent committee “found the drugmaker’s COVID-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of phase-3 trial data,” Reuters cited the biopharmaceutical company to report on Monday.

“No adverse events related to the vaccine had occurred,” the report said.

The vaccine candidate, referred to as Ad5-nCoV, is developed by CanSino Biologics Inc. and the Academy of Military Sciences in China.

CanSino was approved to conduct phase-3 clinical trials in some countries in Europe and Asia, Wu Yuanbin, an official with China’s Ministry of Science and Technology, said in September last year.

Related posts

SpaceX aborts first high-altitude Starship test


High-tech helps boost vaccination campaign


China’s Tianwen-1 probe performs orbital adjustment around Mars